Caffeinism associated with greater use of other psychotropic agents

Caffeinism associated with greater use of other psychotropic agents.

C AFFEINISM, a diagnosis recently included in the third edition of the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM-III),’ is characterized by a constellation of affective, sleep, and psychophysiological manifestations.2 Because symptoms of caffeinism might be confounded or masked by simultaneous ingestion of other drugs, it is pertinent to ask w...

Treatment of dyspnea with psychotropic agents.

Antifungal agents: Polyene, azole, antimetabolite, other and future agents

Antifungals have always been considered as one of the astonishing discoveries of the 20th century. This is correct, but the real marvel is the development of antifungal resistance in hospitals, communities, and the environment concomitant with their use. Fungal infections have emerged as an important clinical threat, with significant associated morbidity and mortality.  This study is desig...

Psychotropic drug use among older adults: prevalence and associated factors.

Objective: Investigating the prevalence of psychotropic drug use among older adults and factors associated with it. Methods: This study was based on the Belo Horizonte Metropolitan Area Health Survey, conducted in 2003. It involved 1,635 elderly (60 years or older) citizens, who were residents of cities within the Belo Horizonte Metropolitan Area and were selected using complex randomize samp...

Cardiac adverse reactions associated with psychotropic drugs

A 10-year cohort study found a 1.33-fold relative risk of death in a schizophrenic population compared with a control population; the leading cause of death was cardiovascular disease. In patients with myocardial infarction and cardiac failure, reduced heart rate variability is one of the predictive factors of increased risk of cardiac death; this reduced heart rate variability might be due to ...